Janssen Pharmaceuticals Inc.

09/06/2023 | Press release | Distributed by Public on 09/06/2023 16:33

Janssen Announces Update to Phase 3 MACiTEPH Study Evaluating Macitentan 75mg in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.